JP5650639B2 - 腫瘍疾患の治療 - Google Patents

腫瘍疾患の治療 Download PDF

Info

Publication number
JP5650639B2
JP5650639B2 JP2011503304A JP2011503304A JP5650639B2 JP 5650639 B2 JP5650639 B2 JP 5650639B2 JP 2011503304 A JP2011503304 A JP 2011503304A JP 2011503304 A JP2011503304 A JP 2011503304A JP 5650639 B2 JP5650639 B2 JP 5650639B2
Authority
JP
Japan
Prior art keywords
ace2
cancer
tumor
activity
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011503304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516501A5 (https=
JP2011516501A (ja
Inventor
ハンザック−ホウラット，エブリン
ロイブナー，ハンス
シャスター，マンフレッド
ピボール，ベルンハード
Original Assignee
アペイロン バイオロジックス アーゲー
アペイロン バイオロジックス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アペイロン バイオロジックス アーゲー, アペイロン バイオロジックス アーゲー filed Critical アペイロン バイオロジックス アーゲー
Publication of JP2011516501A publication Critical patent/JP2011516501A/ja
Publication of JP2011516501A5 publication Critical patent/JP2011516501A5/ja
Application granted granted Critical
Publication of JP5650639B2 publication Critical patent/JP5650639B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011503304A 2008-04-09 2009-04-07 腫瘍疾患の治療 Active JP5650639B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA566/2008 2008-04-09
AT0056608A AT506632A1 (de) 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen
PCT/AT2009/000136 WO2009124330A2 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen

Publications (3)

Publication Number Publication Date
JP2011516501A JP2011516501A (ja) 2011-05-26
JP2011516501A5 JP2011516501A5 (https=) 2012-05-31
JP5650639B2 true JP5650639B2 (ja) 2015-01-07

Family

ID=41130316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011503304A Active JP5650639B2 (ja) 2008-04-09 2009-04-07 腫瘍疾患の治療

Country Status (12)

Country Link
US (1) US8946162B2 (https=)
EP (2) EP2644203A1 (https=)
JP (1) JP5650639B2 (https=)
AT (1) AT506632A1 (https=)
AU (1) AU2009235931B2 (https=)
CA (1) CA2720616C (https=)
DK (1) DK2274005T3 (https=)
ES (1) ES2425308T3 (https=)
NZ (1) NZ588435A (https=)
PL (1) PL2274005T3 (https=)
PT (1) PT2274005E (https=)
WO (1) WO2009124330A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
WO2013182237A1 (en) * 2012-06-06 2013-12-12 Apeiron Biologics Ag Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
KR20150110607A (ko) * 2013-01-14 2015-10-02 아페이론 바이오로직스 아게 변형된 ａｃｅ２ 폴리펩티드
EP3079684B1 (en) * 2013-12-11 2019-11-13 Alterras Therapeutics GmbH Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
WO2018204385A1 (en) * 2017-05-02 2018-11-08 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
US11337909B2 (en) 2017-11-29 2022-05-24 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20230181759A1 (en) * 2020-04-01 2023-06-15 Washington University Compositions for treatment of viral respiratory infections and methods of use thereof
CN112626099A (zh) * 2020-09-29 2021-04-09 清华大学 使用原核细胞发酵表达血管紧张素转化酶2的方法
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
US20250009853A1 (en) 2021-12-03 2025-01-09 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6989363B1 (en) 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
DE60324925D1 (de) * 2002-06-19 2009-01-08 Univ Health Network Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
EP1374907A3 (en) 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Drug transport and delivery system
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid

Also Published As

Publication number Publication date
PT2274005E (pt) 2013-08-27
WO2009124330A3 (de) 2009-12-10
WO2009124330A2 (de) 2009-10-15
CA2720616C (en) 2016-08-09
ES2425308T3 (es) 2013-10-14
CA2720616A1 (en) 2009-10-15
NZ588435A (en) 2012-10-26
US20110033524A1 (en) 2011-02-10
JP2011516501A (ja) 2011-05-26
AU2009235931B2 (en) 2015-07-23
PL2274005T3 (pl) 2013-12-31
AU2009235931A1 (en) 2009-10-15
EP2274005B1 (de) 2013-05-29
US8946162B2 (en) 2015-02-03
EP2274005A2 (de) 2011-01-19
EP2644203A1 (de) 2013-10-02
AT506632A1 (de) 2009-10-15
DK2274005T3 (da) 2013-08-19

Similar Documents

Publication Publication Date Title
JP5650639B2 (ja) 腫瘍疾患の治療
TWI480048B (zh) 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
Xu et al. Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity
US20220267770A1 (en) Compositions and methods of using c/ebp alpha sarna
JP2024103632A (ja) Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法
US20050112061A1 (en) Use of a VEGF antagonist in combination with radiation therapy
JP6782932B2 (ja) Ｎｐｒ−ａアゴニストの新規用途
US7893212B2 (en) S-nitroso group-containing albumin, method for production, and anticancer agent
US10189875B2 (en) Anti-cancer peptide and use thereof
US20220323454A1 (en) Phenothiazines and their derivatives for use as a medicament
CN115803045A (zh) 用于增强放射治疗的包括含有il-2蛋白和cd80蛋白的融合蛋白的药物组合物
CN116327772B (zh) SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法
CN111840541A (zh) 聚肌苷酸胞苷酸联合抗cd47抗体在肿瘤治疗中的应用
CN110215511A (zh) 微肽asrps在治疗癌症中的应用
WO2025256277A1 (zh) 黑素细胞刺激素α-MSH在治疗肝癌中的应用
US20080096793A1 (en) Class III Slrp for the Treatment of Cancer
CN120324579A (zh) 嵌合多肽TAT-Ae单独或联合AKT抑制剂在治疗肿瘤中的应用
KR101658593B1 (ko) Pi4k 동위효소 저해제를 유효성분으로 포함하는 방사선 민감성 증진용 조성물
EA048362B1 (ru) Противораковые белки
US20100284911A1 (en) Preparations and methods for treating malignancies
KR20120127552A (ko) 신경교종 치료를 위한 방사선 및 ｔｒａｉｌ 발현 간엽줄기세포의 조합 치료 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141113

R150 Certificate of patent or registration of utility model

Ref document number: 5650639

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250